| Synthetic - Part 2

Insider Insights: Evaluating the Investment Risks of Beam Therapeutics vs. Intensity Therapeutics

March 19, 2024April 12, 2024 by Simons Chase

In biotech investing, distilling exceptional opportunities from the average (or worse) ventures requires a keen eye on insider activities, financial health, and clinical progress. Beam Therapeutics (BEAM) presents a case that demands caution, with insider stock sales, a substantial accumulated deficit, and limited clinical advancements raising significant concerns. In contrast, Intensity Therapeutics (INTS) is an … Read more

The Future of Cancer Treatment: The Three Most Promising Emerging Therapies

March 4, 2024March 4, 2024 by Simons Chase

Cancer remains one of the world’s leading causes of death. Traditional treatments – surgery, radiation therapy, and chemotherapy – have saved countless lives, yet their limitations are evident. Chemotherapy’s harsh side effects, the potential for recurrence after surgery, and limits to radiation use necessitate new tools in our fight against cancer. Recent breakthroughs in our … Read more

Early-Stage Colon Cancer’s Cloak of Invisibility: Unmasking SOX17

March 3, 2024 by Staff

Our immune system is complex beyond comprehension. It acts as a vigilant guard, constantly patrolling for and eliminating threats like viruses, bacteria, and even abnormal cells that could turn cancerous. Cancer is a cunning adversary. New research from a collaborative effort by scientists at the Massachusetts Institute of Technology (MIT), Dana-Farber Cancer Institute, Harvard Medical … Read more

Goldman Estimates GLP-1 Effects Could Boost GDP by 1%

February 23, 2024February 27, 2024 by Simons Chase

Biotech companies developing GLP-1 agonists for weight loss treatment are being keenly pursued by more mature pharmaceutical companies that have missed the bandwagon so far. This is because use of GLP-1s could increase by 10 – 70 million consumers by 2028, perhaps becoming the largest drug class in history. Reuters reports that the widespread use … Read more

Here Are Three Clinical Stage GLP-1 Agonist Weight Loss Biotechs

February 6, 2024February 22, 2024 by Simons Chase

There is a furious pace of innovation, deal flow and drug approvals for the new class of glucagon-like peptide 1 (GLP-1) receptor agonists and the emerging next gen Dual Agonists for the treatment of obesity and weight loss. Among mature pharmaceutics companies, the bandwagon took off when the sleepy backwater of GLP-1s for diabetes treatment … Read more

An Interview With NeuroBo’s CEO To Discuss The Company’s GLP-1 Dual Agonist

February 1, 2024February 1, 2024 by Simons Chase

NeuroBo Pharmaceuticals is a clinical stage drug development company with a focus on weight loss and a GLP-1 Dual Agonist. Its most advanced drug candidate, A-1726, is a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity. The IND approval is expected soon with Phase 1 trials commencing shortly thereafter. … Read more

Here Is A Promising Non-Toxic CAR-T Therapy Biotech

January 24, 2024February 5, 2024 by Staff

Immix Biopharma (IMMX) is CART-T cell therapy company targeting oncology and immune-dysregulated disease. Immix’s subsidiary Nexcella (94% owned) focuses a CAR-T therapy, NXC-201, which is in clinical trials for the treatment of multiple myeloma and AL amyloidosis (ALA). The company’s other promising therapy, IMX-110, is being investigated in a Phase 1b/2a study for the treatment … Read more

Dual Agonists Push Weight Loss Drug Companies Into Full Bandwagon Mode

January 16, 2024February 21, 2024 by Simons Chase

Brad Loncar, Founder of BiotechTV, observed during an interview in October 2023 that some people were dressed as GLP-1 agonists for Halloween. He was interviewing Dr. Eric Topol, of Scripps Research Institute, who suggested they dress up as skeletons due to how little is known about the mode of action in this class of drugs … Read more

Here Are Two Upcoming Bladder Cancer Therapies

January 4, 2024January 4, 2024 by Simons Chase

According to Persistence Market Research, the global bladder cancer treatment drugs market reached a size of $2bn in 2021 and is estimated to surge to $11.5bn by 2032, advancing at a 17% CAGR from 2022 to 2032. Two companies targeting high-risk non-muscle invasive bladder cancer (NMIBC) are nearing approval of drugs that show great promise. … Read more

Goldman Sachs Launches First-Ever Biotech Fund

January 3, 2024January 3, 2024 by Simons Chase

Investment banking giant Goldman Sachs is making a major move into the life sciences sector with the launch of its first-ever dedicated fund, West Street Life Sciences I. The $650 million fund signals Goldman’s confidence in the burgeoning field and its potential for significant returns despite a recent period of setback and gloom – and … Read more